Pablo Tebas is the director and the PI of the AIDS clinical trial unit of the University of Pennsylvania. He is one of the founding members of the HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group (TSG) of the AIDS clinical trial group. In addition to his ACTG work, he is involved (as PI of the clinical project) in several early phase trials of new compounds developed in conjunction with the NIH in several IPCP grants, including a Phase I study evaluating the antiviral activity of aprepitant (an NK-1R antagonist that down-regulates the expression of CCR5), a phase I study evaluating the immunogenicity of a therapeutic DNA vaccine administered by intramuscular electroporation in collaboration with David Weiner and several gene therapy studies evaluating the therapeutic use of lentiviral vectors in the management of HIV infection (including the use of VIRxSYS 496 –antisense approach-, the first in humans Sangamo’s zinc finger nuclease for CCR5 edition, in collaboration with Dr. Carl June.
Dr. Tebas' clinical interest focus on the treatment of HIV infection and associated infections like hepatitis C. He also has a particular interest in the clinical manifestations and treatment of atypical mycobacterial infections. Dr. Tebas attends the general infectious disease service of the hospital of University of Pennsylvania every year.
